Charmin Sagert, MD
Neurology · Corvallis, ORNPI 1770761215
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,838 of the $32,254 with a category attached, or 70.8%. AbbVie accounts for 99.4% of it on its own, with 3 other manufacturers making up the rest. Among neurology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $658.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Johnson & Johnson$89
- Amgen$72
- Janssen Scientific Affairs, LLC$19
What the payments were for
- Consulting fees$4,59414%
- Speaking & faculty fees$22,83871%
- Travel & lodging$3,27110%
- Food & beverage$1,4635%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $32,074 |
| Johnson & Johnson | 1 | $89 |
| Amgen | 1 | $72 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$30,886
How this compares
$32,254 in reported general payments places this provider in the 90th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 15 | $851,133 |
| CopaxoneGlatiramer Acetate | 38 | $224,865 |
| FingolimodFingolimod Hcl | 13 | $93,832 |
| GlatopaGlatiramer Acetate | 34 | $58,642 |
| Glatiramer Acetate | 22 | $37,390 |
| Emgality PenGalcanezumab-Gnlm | 41 | $32,439 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $17,181 |
| Lacosamide | 37 | $11,198 |
| Pyridostigmine Bromide | 97 | $11,176 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 12 | $8,158 |
| Gabapentin | 157 | $7,152 |
| Dalfampridine ErDalfampridine | 19 | $5,389 |
| Mycophenolate Mofetil | 34 | $4,489 |
| Sumatriptan Succinate | 36 | $4,312 |
| Baclofen | 58 | $3,104 |
Paid to pharmacies, not to this prescriber.
Other neurology in Corvallis
- Sydney PierceyCorvallis$26K
- David ClarkSpringfield$1.1M
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Walter CarliniMedford$425K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.